Browse studies

Find your next paid study

7 recruiting studies matching your filters

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462…

Progressive Metastatic Castrate Resistant Prostate Cancer

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07206056

Phase 2

An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients…

Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT04038502

Phase 1

A Phase 1/1b, Open-Label, First-in-Human Multicenter Study to Assess the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Pharmacodynamics of Oral TT-10 (an Adenosine 2A Receptor Antagonist), and TT-4 Diacid (an Adenosine 2B Receptor Antagonist), as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have fail…

Renal Cell CancerCastrate Resistant Prostate CancerNon Small Cell Lung Cancer+1 more

Estimated

~$10 – $8,750

Portage BiotechNCT04969315

Phase 2

A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Metastatic Castration Resistant Prostate Cancer

This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with p…

Castrate Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerProstate Cancer+1 more

Estimated

~$10 – $5,625

University of California, San FranciscoNCT05766371

Phase 1

A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more

Estimated

~$10 – $8,750

Epigenetix, Inc.NCT05488548

Phase 1

A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally …

Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pha…

Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+10 more

Estimated

~$10 – $8,750

858 Therapeutics, Inc.NCT06395519